Morgan Stanley
ACRS icon

Morgan Stanley’s Aclaris Therapeutics ACRS Stock Holding History

Morgan Stanley’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.3M Sell
2,746,302
-669,088
-20% -$2.26M ﹤0.01% 3551
2025
Q4 		$10.3M Sell
3,415,390
-661,856
-16% -$1.67M ﹤0.01% 3586
2025
Q3 		$7.75M Buy
4,077,246
+537,054
+15% +$936K ﹤0.01% 3775
2025
Q2 		$5.03M Buy
3,540,192
+1,124,608
+47% +$1.52M ﹤0.01% 4062
2025
Q1 		$3.7M Buy
2,415,584
+1,343,800
+125% +$2.87M ﹤0.01% 4180
2024
Q4 		$2.66M Buy
1,071,784
+591,011
+123% +$1.47M ﹤0.01% 4499
2024
Q3 		$553K Buy
480,773
+294,430
+158% +$361K ﹤0.01% 5354
2024
Q2 		$205K Sell
186,343
-305,323
-62% -$359K ﹤0.01% 5664
2024
Q1 		$610K Sell
491,666
-1,460,092
-75% -$1.74M ﹤0.01% 5218
2023
Q4 		$2.05M Buy
1,951,758
+253,367
+15% +$773K ﹤0.01% 4911
2023
Q3 		$11.6M Buy
1,698,391
+63,576
+4% +$543K ﹤0.01% 2983
2023
Q2 		$17M Buy
1,634,815
+958,197
+142% +$8.67M ﹤0.01% 2637
2023
Q1 		$5.47M Buy
676,618
+536,214
+382% +$6.81M ﹤0.01% 3711
2022
Q4 		$2.21M Sell
140,404
-27,408
-16% -$441K ﹤0.01% 4394
2022
Q3 		$2.64M Buy
167,812
+6,702
+4% +$106K ﹤0.01% 4239
2022
Q2 		$2.25M Buy
161,110
+130,171
+421% +$1.82M ﹤0.01% 4439
2022
Q1 		$532K Sell
30,939
-11,930
-28% -$163K ﹤0.01% 5368
2021
Q4 		$623K Buy
42,869
+10,397
+32% +$158K ﹤0.01% 5409
2021
Q3 		$585K Buy
32,472
+9,133
+39% +$146K ﹤0.01% 5391
2021
Q2 		$410K Buy
23,339
+14,465
+163% +$329K ﹤0.01% 5648
2021
Q1 		$224K Sell
8,874
-9,329
-51% -$182K ﹤0.01% 5594
2020
Q4 		$118K Sell
18,203
-2,056
-10% -$8.67K ﹤0.01% 5842
2020
Q3 		$52K Buy
20,259
+6,713
+50% +$15K ﹤0.01% 5707
2020
Q2 		$22K Buy
13,546
+9,724
+254% +$13K ﹤0.01% 5978
2020
Q1 		$3K Sell
3,822
-2,515,160
-100% -$3.42M ﹤0.01% 6303
2019
Q4 		$4.76M Buy
2,518,982
+790,841
+46% +$1.31M ﹤0.01% 3256
2019
Q3 		$1.87M Buy
1,728,141
+1,560,779
+933% +$2.21M ﹤0.01% 3860
2019
Q2 		$367K Sell
167,362
-39,393
-19% -$215K ﹤0.01% 4755
2019
Q1 		$1.24M Buy
206,755
+39,712
+24% +$263K ﹤0.01% 3966
2018
Q4 		$1.23M Sell
167,043
-216,775
-56% -$2.23M ﹤0.01% 4127
2018
Q3 		$5.57M Buy
383,818
+317,847
+482% +$5.45M ﹤0.01% 3066
2018
Q2 		$1.32M Sell
65,971
-50,607
-43% -$935K ﹤0.01% 4425
2018
Q1 		$2.04M Sell
116,578
-71,137
-38% -$1.51M ﹤0.01% 3997
2017
Q4 		$4.63M Buy
187,715
+154,737
+469% +$3.77M ﹤0.01% 3192
2017
Q3 		$851K Buy
32,978
+13,004
+65% +$349K ﹤0.01% 4536
2017
Q2 		$541K Buy
19,974
+444
+2% +$12.1K ﹤0.01% 4750
2017
Q1 		$583K Sell
19,530
-39,276
-67% -$1.13M ﹤0.01% 4745
2016
Q4 		$1.59M Buy
58,806
+31,869
+118% +$813K ﹤0.01% 4118
2016
Q3 		$690K Buy
26,937
+26,823
+23,529% +$569K ﹤0.01% 4304
2016
Q2 		$2K Buy
+114
New +$2.26K ﹤0.01% 6357
2016
Q1 		– Sell
-391
Closed -$11K – 6552
2015
Q4 		$11K Buy
+391
New +$7.62K ﹤0.01% 6206

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Morgan Stanley's ACRS Position: Q1 2026 in Review

Morgan Stanley reduced its Aclaris Therapeutics (ACRS) stake by 20% in Q1 2026, selling an estimated $2.26M and leaving 2,746,302 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3551.

Morgan Stanley first reported a position in ACRS in Q4 2015 and has held it in 41 quarters since. The position peaked at $17M in Q2 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Morgan Stanley held 2,746,302 shares of Aclaris Therapeutics worth $10.3M as of Q1 2026.
  • Morgan Stanley sold 669,088 Aclaris Therapeutics shares in Q1 2026, an estimated $2.26M.
  • Aclaris Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3551 holding.
  • Morgan Stanley first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 41 quarters since.
  • Morgan Stanley's Aclaris Therapeutics position peaked at $17M in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.